NCT06600022招募中1 期
A Phase I/II, Open-label, Multicentre, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics and Anti-tumor Activity of SCTB41 in Patients with Advanced Malignant Solid Tumours
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 441
- 试验地点
- 1
- 主要终点
- Dose-Limiting toxicity(DLT)
研究概览
简要总结
This study aims to explore the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB41 as a monotherapy in adult patients with advanced malignant solid tumours. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntarily sign the informed consent form (ICF);
- •Male or female, ≥18 years old;
- •Survival duration more than 3 months;
- •ECOG score ≤ 1 point;
- •Participants in Phase Ia (dose-escalation phase) are required to meet the following criteria: histologically or cytologically confirmed diagnosis of advanced malignant solid tumour;
- •Participants in Phase Ib (dose-expansion phase) and Phase II are required to meet the following criteria: Histologically or cytologically confirmed specific type advanced malignant solid tumours;
- •Adequate organ and bone marrow function.
排除标准
- •Participants with brainstem, meningeal, spinal metastases, orcompression; active central nervous system metastases;
- •Other malignancies diagnosed;
- •History of hypertensive crisis or hypertensive encephalopathy; presence of uncontrolled hypertension. History of arterial thrombosis or deep veinthrombosis within 6 months prior to enrollment;
- •Presence of any active autoimmune disease or a history of autoimmunedisease with an expected recurrence;
- •Received chemotherapy, immunotherapy, biologic therapy, or other antitumor treatments within 4 weeks before enrollment;
- •Need for immunosuppressive drugs within 2 weeks prior to enrollment oranticipated during the study;
- •Significant coagulopathy or other evident risk of bleeding;
- •uncontrolled effusions in the serous cavities within 4 weeks before enrollment；
- •Major surgery or significant trauma within 4 weeks prior to enrollment;presence of unhealed skin wounds, surgical sites, trauma sites, severe- Page 3 of 4 [DRAFT] -mucosal ulcers, or fractures, or if the Investigator deems the participantunsuitable for the study;
- •History of permanent discontinuation of immunotherapy due to immunerelated toxicity or occurrence of ≥ Grade 3 irAEs;
- •Known severe allergy to similar antibody drugs;
- •Presence of active infection；
- •History of organ transplantation or stem cell transplantation;
- •Pregnant or breastfeeding female; women of childbearing potential withpositive pregnancy test within 7 days before the enrollment; participants(including males of childbearing potential and their female partners, and females of childbearing potential and their male partners) unwilling to use medically recognized effective contraception during the study and for 6 months after treatment ends.
研究组 & 干预措施
Arms
Experimental
SCTB41 of different doses,IV,every 3 weeks
干预措施: SCTB41 (Drug)
结局指标
主要结局
Dose-Limiting toxicity(DLT)
时间窗: :From Day 0 up to Day 21
Incidence of dose-limiting toxicities up to the Day 21 visit
Objective response rate (ORR)
时间窗: Up to 2 years
The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR, based on RECIST Version 1.1
次要结局
- Disease control rate (DCR)(Up to 2 years)
- Overall survival (OS)(Up to 2 years)
- Progression-free survival (PFS)(Up to 2 years)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
1 期
Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours.Advanced Malignant Solid TumoursNCT06304818Sinocelltech Ltd.515
已完成
1 期
Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid TumorsAdvanced CancerNCT03352531Akesobio Australia Pty Ltd99
已完成
1 期
Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid TumorsAdvanced CancerNCT03261011Akesobio Australia Pty Ltd119
已完成
1 期
A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid TumorsNeoplasms MalignantNCT04047290Akesobio Australia Pty Ltd80
已完成
早期 1 期
A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid TumoursAdvanced or Metastatic Solid TumoursNCT05021120Akesobio Australia Pty Ltd67